Christiana Blair

TL;DR: In patients with severe Covid-19 not requiring mechanical ventilation, a randomized, open-label, phase 3 trial involving hospitalized patients with confirmed SARS-CoV-2 infection, oxygen saturation of 94% or less while they were breathing ambient air, and radiologic evidence of pneumonia, the magnitude of benefit cannot be determined.

TL;DR: Among patients with moderate COVID-19, those randomized to a 10-day course of remdesivir did not have a statistically significant difference in clinical status compared with standard care at 11 days after initiation of treatment, but the difference was of uncertain clinical importance.

TL;DR: Among participants with pulmonary arterial hypertension who had not received previous treatment, initial combination therapy with ambrisentan and tadalafil resulted in a significantly lower risk of clinical-failure events than the risk with am debrisentan or tadalAFil monotherapy.

TL;DR: This post hoc subgroup analysis provides evidence that CTD-PAH and SSc-PAh patients benefit from initial ambrisentan and tadalafil combination therapy.

TL;DR: Six-minute walk distance and brain natriuretic peptide levels at baseline and after initiation of treatment have been associated with survival in patients with pulmonary arterial hypertension, but values at baseline or week 12 identifi ed a population with an elevated risk of death at 2 years.